Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients

Anticancer Research

Volumn 25, Issue 5, 2005, Pages 3607-3612

  Zojer, Niklas ^a   Brenner, Karin ^a   Beke, Dora ^a   Kudlacek, Stefan ^b,d   Hawa, Gerhard ^c   Woloszczuk, Wolfgang ^c,d   Hofbauer, Lorenz C ^e   Pecherstorfer, Martin ^a,f  

^a First Department of Medicine and Medical Oncology   (Austria)

^b KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^c Biomedica Group   (Austria)

^d Boltzmann Institut für Altersforschung   (Austria)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

^f 1st Dept of Medicine and Oncology   (Austria)

Author keywords

Bisphosphonates; Hypercalcemia; Osteoprotegerin; RANKL

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; IBANDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HYPERCALCEMIA; MALE; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; CARRIER PROTEINS; DIPHOSPHONATES; FEMALE; GLYCOPROTEINS; HUMANS; HYPERCALCEMIA; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASMS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 23344445607     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Parfitt AM, Mundy GR, Roodman GD, Hughes DE and Boyce BF: A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res 11: 150-159, 1996.
2. Lacey DL, Timms E, Tan HL et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176, 1998.
3. Simonet WS, Lacey DL, Dunstan CR et al: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319, 1997.
4. Goltzman D: Osteolysis and cancer. J Clin Invest 107: 1219-1220, 2001.
5. Mundy GR and Guise TA: Hypercalcemia of malignancy. Am J Med 103: 134-145, 1997.
6. Sezer O, Heider U, Zavrski I, Kühne CA and Hofbauer LC: RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101: 2094-2108, 2003.
7. Roodman GD: Mechanisms of bone metastasis. N Engl J Med 350: 1655-1664, 2004.
8. Pecherstorfer M, Zimmer-Roth I, Schilling T et al: The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 80: 97-103, 1995.
9. Theriault RL and Hortobagyi GN: The evolving role of bisphosphonates. Semin Oncol 28: 284-290, 2001.
10. Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P and Willvonseder R: Austrian Study Group on Normative Values of Bone Metabolism. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 32: 681-686, 2003.
11. Hawa G, Brinskelle-Schmal N, Glatz K, Maitzen S and Woloszczuk W: Immunoassay for soluble RANKL (receptor activator of NF-κB ligand) in serum. Clin Lab 49: 461-463, 2003.
12. Viereck V, Emons G, Lauck V et al: Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291: 680-686, 2002.
13. Pan B, Farrugia AN, To LB et al: The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Mineral Res 19: 147-154, 2004.
14. Kim YH, Kim GS and Jeong-Hwa B: Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. Exp Mol Med 34: 145-151, 2002.
15. Voskaridou E, Terpos E, Spina G et al: Pamidronate is an effective treatment for osteoporosis in patients with betathalassaemia. Br J Haematol 123: 730-737, 2003.
16. Alvarez L, Peris P, Guanabens N et al: 2003 Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis Rheum 48: 824-828, 2003.
17. Rogers MJ, Gordon S, Benford HL et al: Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88(12 Suppl): 2961-2978, 2000.
18. Grimaud E, Soubigou L, Couillaud S et al: Receptor activator of nuclear factor kB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 163: 2021-2031, 2003.
19. Standal T, Seidel C, Hjertner O et al: Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 100: 3002-3007, 2002.
20. Terpos E, Szydlo R and Apperley JF: Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102: 1064-1069, 2003.
21. Capparelli C, Kostenuik PJ, Morony S et al: Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 60: 783-787, 2000.
22. Body JJ, Greipp P, Coleman RE et al: A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97(3 Suppl): 887-892, 2003.
23. Giuliani N, Colla S, Sala R et al: Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 100: 4615-4621, 2002.
24. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL and Riggs BL: Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111: 1221-1230, 2003.
25. Jung K, Lein M, Stephan C et al: Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 111: 783-791, 2004.
26. Schett G, Kiechl S, Redlich K et al: Soluble RANKL and risk of nontraumatic fracture. JAMA 291: 1108-1113, 2004.